These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 28140088)

  • 1. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1S2):25-29. PubMed ID: 28140088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trial.
    Hainsworth JD
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):25-9. PubMed ID: 11842385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma.
    Hainsworth JD; Litchy S; Burris HA; Scullin DC; Corso SW; Yardley DA; Morrissey L; Greco FA
    J Clin Oncol; 2002 Oct; 20(20):4261-7. PubMed ID: 12377971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma.
    Hainsworth JD
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):9-15. PubMed ID: 12652459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab as first-line systemic therapy for patients with low-grade lymphoma.
    Hainsworth JD
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):25-9. PubMed ID: 11225997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA
    J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonging remission with rituximab maintenance therapy.
    Hainsworth JD
    Semin Oncol; 2004 Feb; 31 Suppl 2():17-21. PubMed ID: 28140104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonging remission with rituximab maintenance therapy.
    Hainsworth JD
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):17-21. PubMed ID: 15042530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1S2):56-69. PubMed ID: 28140093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
    Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: Ongoing and future clinical development.
    Grillo-López AJ; Hedrick E; Rashford M; Benyunes M
    Semin Oncol; 2002 Feb; 29(1S2):105-112. PubMed ID: 28140083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
    J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging information on the use of rituximab in chronic lymphocytic leukemia.
    Keating MJ; O'Brien S; Albitar M
    Semin Oncol; 2002 Feb; 29(1S2):70-74. PubMed ID: 28140094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
    Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
    J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of mitoxantrone in the treatment of indolent lymphomas.
    Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL
    Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Litchy S; Barton JH; Houston GA; Hermann RC; Bradof JE; Greco FA;
    J Clin Oncol; 2003 May; 21(9):1746-51. PubMed ID: 12721250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
    Leahy MF; Seymour JF; Hicks RJ; Turner JH
    J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
    Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
    Leonard JP; Link BK
    Semin Oncol; 2002 Feb; 29(1S2):81-86. PubMed ID: 28140096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.